Armata Pharmaceuticals Stock Surges 300% on Promising Antibacterial Therapy Data
Armata Pharmaceuticals (ARMP) shares skyrocketed nearly 300% Wednesday after the biotech firm unveiled encouraging Phase 2a trial results for its experimental phage therapy AP-SA02. The treatment targets antibiotic-resistant Staphylococcus aureus bacteremia, a lethal bloodstream infection.
The Defense Department-funded study showed 88% of patients receiving AP-SA02 with standard antibiotics improved by Day 12, compared to 58% on antibiotics alone. Safety data proved favorable, with only mild side effects reported in 6% of treatment-group patients.
CEO Deborah Birx hailed the findings as a critical milestone in combating antimicrobial resistance. The company plans to advance the phage therapy into Phase 3 trials by 2026, pending regulatory consultations.
